IBA - Huge miss, H2 ought to be better
Huge miss on H1 23 results with Group REBIT landing at EUR -20m, mainly impacted by phasing in PT revenues recognition with more installations initially planned for H2 and delays at client side, postposing some installations to H2. Management indicates that based on visibility on backlog conversion and operational measures in place, they expect significant ramp-up in H2 23 with the bulk of FY23 revenue recognition skewed towards H2. These results came as a negative surprise to us. We will review our estimates and TP following this update and today's analyst meeting. BUY reiterated.IBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.